Jeannette Potts Sells 3,412 Shares of uniQure (NASDAQ:QURE) Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 3,412 shares of uniQure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $30,912.72. Following the completion of the sale, the insider owned 138,483 shares of the company’s stock, valued at $1,254,655.98. This trade represents a 2.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

uniQure Trading Up 34.0%

Shares of QURE traded up $3.62 during mid-day trading on Friday, reaching $14.27. The company had a trading volume of 16,602,429 shares, compared to its average volume of 3,442,688. The stock has a market cap of $892.30 million, a price-to-earnings ratio of -4.14 and a beta of 0.73. The company has a current ratio of 10.43, a quick ratio of 7.12 and a debt-to-equity ratio of 0.25. The firm has a fifty day simple moving average of $22.25 and a 200-day simple moving average of $29.44. uniQure N.V. has a fifty-two week low of $7.76 and a fifty-two week high of $71.50.

uniQure (NASDAQ:QURE) last issued its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The firm had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%. On average, sell-side analysts anticipate that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Institutional Trading of uniQure

Several hedge funds have recently made changes to their positions in QURE. Woodline Partners LP grew its holdings in uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares during the period. Teacher Retirement System of Texas acquired a new stake in uniQure in the 2nd quarter valued at about $151,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of uniQure during the 2nd quarter valued at about $215,000. SG Americas Securities LLC acquired a new position in shares of uniQure in the 2nd quarter worth approximately $1,321,000. Finally, Main Management ETF Advisors LLC raised its holdings in shares of uniQure by 1.6% in the 2nd quarter. Main Management ETF Advisors LLC now owns 56,420 shares of the biotechnology company’s stock worth $786,000 after purchasing an additional 912 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on QURE shares. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a research report on Tuesday. William Blair reissued a “market perform” rating on shares of uniQure in a research report on Tuesday, November 11th. Chardan Capital reduced their price objective on uniQure from $53.00 to $16.00 and set a “buy” rating on the stock in a research note on Tuesday. Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday. Finally, Barclays assumed coverage on uniQure in a report on Tuesday, January 27th. They set an “equal weight” rating and a $31.00 target price on the stock. Seven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $34.33.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Neutral Sentiment: Mizuho issued a neutral rating on QURE, keeping some analyst coverage tepid rather than bullish. Read More.
• Negative Sentiment: A senior FDA official publicly called uniQure’s Huntington’s disease therapy unsuccessful and defended the agency’s call for a new randomized, placebo‑controlled study — a move that raises the likelihood of delays and additional trials before any BLA. Read More.
• Negative Sentiment: Broad media coverage amplifies regulatory risk: multiple outlets (WSJ, CNBC, FierceBiotech, BioSpace) report public rebukes from FDA/HHS and intensifying back‑and‑forth with uniQure — increasing reputational and approval uncertainty. Read More.
• Negative Sentiment: Numerous class‑action and shareholder‑lawsuit notices filed and circulated by law firms (lead‑plaintiff deadline April 13, 2026) — these raise potential legal liability, management distraction, and ongoing downward pressure on the share price. Read More.
• Negative Sentiment: Analyst actions have turned negative: Chardan cut its price target and other outlets report pessimistic forecasts (Goldman Sachs coverage noted), contributing to recent downgrades and reduced sell‑side enthusiasm. Read More.
• Negative Sentiment: Multiple insiders (including the CEO and CFO) sold shares on March 4 at ~$9.06 — the CEO, CFO and other insiders reduced holdings by low single‑digit to ~5% amounts. Insider selling can be perceived negatively by the market even though insiders still hold large positions. Read More.
• Negative Sentiment: Short‑term price shock: Zacks and other outlets report the stock plunged ~32% in a week after the FDA said AMT‑130 Phase I/II data are insufficient as primary evidence for a marketing application — underscores how quickly regulatory comments can swing valuation. Read More.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.